Physician profile
Steven Gary Fein
NPI 1437146552
$1,032,966.37
in general payments reported to CMS, 2019-2025
43 companies · $87K in 2025
The $87K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156K · 2020: $148K · 2021: $288K · 2022: $169K · 2023: $94K · 2024: $91K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $84K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Travel and Lodging: $54K · Consulting Fee: $48K · Food and Beverage: $6,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $84,030.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,736.00 |
| Travel and Lodging | $53,671.57 |
| Consulting Fee | $47,819.50 |
| Food and Beverage | $6,346.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $178,127.38 | 2021-2025 | Monoferric |
| Amgen INC. | $148,922.90 | 2019-2024 | Nplate |
| Dova Pharmaceuticals | $106,726.72 | 2019-2021 | |
| Daiichi Sankyo INC. | $97,721.46 | 2019-2022 | |
| Agios Pharmaceuticals, INC. | $95,931.98 | 2022-2025 | Pyrukynd |
| Sobi, INC | $86,247.41 | 2022-2024 | |
| Incyte Corporation | $58,609.42 | 2019-2025 | Jakafi |
| Pfizer INC. | $47,044.40 | 2019-2021 | |
| Genzyme Corporation | $40,834.50 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $30,293.18 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $29,344.27 | 2019-2024 | |
| Beigene USA, INC. | $27,506.36 | 2021-2023 | Brukinsa |
| Btg International INC. | $23,158.62 | 2020-2022 | |
| Celgene Corporation | $21,421.36 | 2019-2020 | |
| American Regent | $15,198.61 | 2024-2025 | Injectafer |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $7,827.94 | 2019-2022 | |
| Kite Pharma, INC. | $3,330.00 | 2020-2021 | |
| Octapharma USA, INC. | $3,121.44 | 2022-2023 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Teva Pharmaceuticals USA, INC. | $2,330.00 | 2020 | |
| Bioverativ Therapeutics INC. | $2,012.00 | 2019 | |
| Janssen Research & Development, LLC | $1,501.77 | 2022 | |
| Servier Pharmaceuticals LLC | $1,449.36 | 2021-2023 | |
| Epizyme, INC. | $1,329.99 | 2021 | |
| Seagen INC. | $1,239.63 | 2019-2023 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $814.49 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.27 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.29 | 2020-2021 | |
| Stemline Therapeutics INC. | $117.75 | 2019 | |
| Emd Serono, INC. | $80.61 | 2022-2023 | Bavencio |
| Astellas Pharma US INC | $75.99 | 2020 | |
| Terumo Bct, INC. | $63.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $58.09 | 2021 | |
| Merck Sharp & Dohme LLC | $55.93 | 2023 | Keytruda, Lynparza |
| Reflexion Medical, INC. | $43.07 | 2023 | Reflexion Medical Radiotherapy System |
| Astrazeneca Pharmaceuticals Lp | $40.43 | 2022-2023 | Imfinzi |
| Recordati_rare_diseases_inc. | $21.12 | 2024 | Sylvant |
| Genentech USA, INC. | $20.08 | 2023 | Phesgo, Kadcyla, Perjeta |
| Janssen Biotech, INC. | $19.75 | 2022 | |
| G1 Therapeutics, INC. | $18.96 | 2023 | Cosela |
| Abbvie INC. | $15.36 | 2020 | |
| Taiho Oncology, INC. | $12.98 | 2022 | |
| Janssen Scientific Affairs, LLC | $6.50 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Fein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.